Case Study: A Reassuring Pace of Aging, Hiding a Metabolic Story

When the Pace of Aging Looks Fine but the Metabolic Picture Doesn't

A recurring question from providers: "My patient's overall aging numbers look good — so why should I keep digging?" This case walks through a real report pair where that instinct would have missed the most clinically important finding.

The patient

Dana, 39, female. No major diagnoses. Presents for a longevity-focused wellness visit, generally active, reports occasional wine most evenings. Runs a combined TruAge + TruHealth panel as a baseline.

TruAge: a reassuring opening picture

At first glance, Dana's results look like a win:

If a provider stopped here, the conversation would be short: "Your biology looks good — keep doing what you're doing."

But the organ-level and structural clocks tell a different story

Breaking SymphonyAge down by organ system shows the elevation isn't evenly distributed. Inflammation (47.2), Metabolic (44.6), Musculoskeletal (44.6), Heart (44.6), Liver (44.4), Kidney (44.0), and Hormone (44.0) are all running older than chronological age — with Inflammation the single most elevated system. Lung (36.4) is the outlier in the other direction.

This is the discordance pattern worth teaching: OMICm Age and DunedinPACE are more global, current-state signals. SymphonyAge and telomere age are picking up something concentrated in specific systems that the whole-body pace metrics can dilute out. Neither is "wrong" — they're answering different questions, and here they disagree in a clinically useful way.

Opening TruHealth to find out why

With Inflammation and Metabolic flagged as the two most-elevated organ systems, that's where to look first in TruHealth.

Metabolic Markers land in the Critical range (17th percentile) — the single worst category on the panel:

Serum Lipids are Suboptimal (24th percentile), and the pattern matters more than any single number:

This is exactly the scenario where a routine lipid panel can mislead: normal-to-low LDL-C, reviewed in isolation, hides a small-dense-LDL-plus-high-triglyceride phenotype that's more atherogenic, not less.

Inflammation Markers (Suboptimal, 30th percentile) and a critically low Sphingomyelins result (1st percentile, flagged) line up with the elevated Inflammation organ age — sphingomyelin depletion is tied to membrane integrity and neuro/metabolic signaling, and is one of the few markers in this report flagged as critically out of range.

Liver, kidney, and uric acid findings reinforce each other across both reports: Alkaline Phosphatase, BUN, and Creatinine were flagged high in TruAge; Cystatin-C (93rd percentile) and Urate (99th percentile, critically high) are flagged in TruHealth. Phenylacetylglutamine — a gut-derived, kidney-relevant metabolite — shows up as elevated in both reports independently, which is a useful cross-validation point to show a provider unfamiliar with how the two products corroborate each other.

One more data point worth surfacing in conversation: the epigenetic Alcohol Biomarker sits in High Risk (87.8th percentile) — plausibly connected to the liver/kidney/uric-acid cluster above, and worth asking about directly rather than inferring.

Clinical next steps

The takeaway

Dana's DunedinPACE and OMICm Age would have supported a "you're doing great" conversation. Her Symphony Age, telomere age, and TruHealth panel told a more urgent story — an insulin-resistant, atherogenic lipid pattern partly masked by a reassuring LDL-C, sitting alongside real inflammatory and liver/kidney signal. The two layers didn't contradict each other; the discordance was the finding. That's the habit worth building: when the pace-of-aging number looks good, use TruHealth to check whether it's good everywhere — or just on average.

Note: patient details in this case are fictionalized; the report pair is real.